cannavest cbd oil

Cannabidiol (CBD) oil is a naturally occurring constituent of industrial hemp and marijuana collectively called cannabis. CBD oil is one of at least 85 cannabinoid compounds found in cannabis and is popular for its medicinal benefits. After tetrahydrocannabinol (THC), which is the most abundant compound in cannabis, CBD is the second most abundant. Other names for CBD oil include CBD-rich hemp oil, hemp-derived CBD oil, or CBD-rich cannabis oil. CBD is generally considered to be safe and has been used medicinally for decades. The suggested medicinal effects of CBD include decreasing anxiety, improving sleep, and providing other neuroprotective effects.

Presenting Concerns

This case study illustrates the use of cannabidiol (CBD) oil to decrease the addictive use of marijuana and provide anxiolytic and sleep benefits. Addiction to marijuana is a chronic, relapsing disorder, which is becoming a prevalent condition in the United States. The most abundant compound in the marijuana, which is called tetrahydrocannabinol (THC), has been widely studied and known for its psychoactive properties. The second most abundant component—CBD—has been suggested to have the medicinal effects of decreasing anxiety, improving sleep, and other neuro-protective effects. The mechanism of action for CBD has been suggested to be antagonistic to the psychoactive properties of THC in many locations within the central nervous system. Such action raises the issue of whether it might be beneficial to use CBD in isolation to facilitate withdrawal of marijuana use. The specific use of CBD for marijuana reduction has not been widely studied.

Clinical Findings

In time, the patient’s marijuana habit progressed to addiction. In May 2015, it was recommended that he begin taking CBD as a way of transitioning off the daily marijuana use and stabilizing his erratic moods.

Cannavest cbd oil

Cannavest, in common with a number of other development stage companies, has shown marked volatility in its earnings statements. The company reported a loss of $2 million on sales of $2.4 million in the quarter. This was a steep drop from the same quarter a year previously, but results in that quarter were skewed by a $7.9 million paper transaction involving two subsidiaries. In the current quarter, the company also reported another confounding factor, that being the settlement of a lawsuit with another cannabis company, which netted Cannavest $150,000 in the quarter and is expected to yield $750,000 over time.

Cannavest has been moving forward with development of its PlusCBD Oil brand, based on cannabidiol, the non-narcotic fraction of the cannabis plant. The Food and Drug Administration has said that CBD is not a legal dietary ingredient for dietary supplements, but that has not prevented companies from moving forward with development of functional foods featuring the molecule.

Image © iStockPhoto / Zzvet

Food status provides regulatory relief

One of the regulatory workarounds that Cannavest and others in the sector use is hemp’s status as a food. Industrial hemp, usually defined that plants that have less than 0.3% THC content, the narcotic component of the plant, is being grown in test plots in Kentucky with the majority of its hemp supply coming from Europe.

“Our branded products are positioned to take advantage of the market demand for cannabidiol and CBD-based products. We continue to provide the market leadership in ‘mainstreaming’ CBD as a dietary supplement, beauty care product, and, as an ingredient for numerous other products from pet foods, vape products and specialty beverages,”​ said Cannavest CEO Michael Mona Jr.